Holen Sie sich die Stockscreener-App
2.64
0.76%
0.02
Vorhandelsmarkt:
2.68
0.04
+1.52%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$2.62
Offen:
$2.65
24-Stunden-Volumen:
3.57M
Relative Volume:
0.95
Marktkapitalisierung:
$513.41M
Einnahmen:
$36,000
Nettoeinkommen (Verlust:
$-91.08M
KGV:
-2.8157
EPS:
-0.9376
Netto-Cashflow:
$-71.67M
1W Leistung:
+1.15%
1M Leistung:
-7.37%
6M Leistung:
-48.13%
1J Leistung:
-61.68%
1-Tages-Spanne:
$2.62
$2.71
1-Wochen-Bereich:
$2.5702
$2.71
52-Wochen-Spanne:
$2.56
$7.73
Altimmune Inc Stock (ALT) Company Profile
Firmenname
Altimmune Inc
Sektor
Branche
Telefon
(240) 654-1450
Adresse
910 CLOPPER ROAD, GAITHERSBURG, MD
Compare ALT vs VRTX, REGN, ARGX, ALNY, RVMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALT
Altimmune Inc
|
2.64 | 513.41M | 36,000 | -91.08M | -71.67M | -0.9376 |
VRTX
Vertex Pharmaceuticals Inc
|
458.99 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
607.93 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
892.26 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
282.72 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.77 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Altimmune Inc Stock (ALT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-24 | Hochstufung | Goldman | Sell → Neutral |
| 2026-03-18 | Eingeleitet | Truist | Buy |
| 2026-01-28 | Eingeleitet | Barclays | Overweight |
| 2025-07-10 | Fortgesetzt | Goldman | Sell |
| 2025-02-28 | Eingeleitet | William Blair | Mkt Perform |
| 2025-01-08 | Eingeleitet | Stifel | Buy |
| 2024-11-12 | Eingeleitet | UBS | Buy |
| 2024-04-29 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-01-24 | Eingeleitet | Goldman | Neutral |
| 2023-03-22 | Herabstufung | Goldman | Buy → Neutral |
| 2022-12-01 | Eingeleitet | Goldman | Buy |
| 2021-12-29 | Fortgesetzt | Jefferies | Buy |
| 2021-06-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-02-11 | Eingeleitet | Guggenheim | Buy |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-11-12 | Bestätigt | B. Riley Securities | Buy |
| 2020-09-25 | Eingeleitet | B. Riley FBR | Buy |
| 2020-08-14 | Eingeleitet | Evercore ISI | Outperform |
| 2020-07-31 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-28 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2020-02-24 | Fortgesetzt | ROTH Capital | Buy |
| 2019-07-19 | Eingeleitet | ROTH Capital | Buy |
| 2017-10-09 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Altimmune Inc Aktie (ALT) Neueste Nachrichten
ALT Stock Drops On Wider-Than-Expected Q4 Loss: Retail Voices Hopes For Deal To Alleviate Cash Concerns - Stocktwits
Altimmune sets pemvidutide's phase 3 MASH playbook as AUD data near - MSN
ALT stock guide to pemvidutide's MASH, AUD and ALD setup - MSN
LULU, LCID, ALT Stocks Hit 52-Week Lows Today: What's Driving The Selloff? - Stocktwits
Why is Altimmune (ALT) down 11.3% since last earnings report? - MSN
Why Is Altimmune (ALT) Down 11.3% Since Last Earnings Report? - Yahoo Finance
Altimmune touts pemvidutide momentum ahead of phase 3 MASH trial - MSN
Is Altimmune worth buying ahead of 2026 catalysts? - MSN
Here's why you should add Altimmune stock to your portfolio now - MSN
Altimmune Sets Pemvidutide’s Phase 3 MASH Playbook as AUD Data Near - Yahoo Finance
Alcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsight - GlobeNewswire Inc.
Altimmune Shares Drop After $225 Million Offering Prices - Moomoo
ALT and the Rise of Dual Agonists Targeting Liver Disease - Yahoo Finance
ALT Stock Guide to Pemvidutide's MASH, AUD and ALD Setup - Yahoo Finance
Is Altimmune Worth Buying Ahead of 2026 Catalysts? - Yahoo Finance
Altimmune (ALT) Gains Ground Amid Positive Momentum, Testing Key Resistance LevelsHedge Fund Exposure - newsline.com
ALT Stock Has Nearly Halved In The Past Year, So Why Does Wall Street See Almost 500% Upside? - Stocktwits
Altimmune Touts Pemvidutide Momentum Ahead of Phase 3 MASH Trial - Barchart.com
Altimmune director Gill buys $31k in company stock - Investing.com
ALT: Pemvidutide's phase III MASH trial advances with strong data, funding, and regulatory alignment - TradingView
SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune - TMX Newsfile
Citizens reiterates Altimmune stock rating on fibrosis trial data - Investing.com
Citizens reiterates Altimmune stock rating on fibrosis trial data By Investing.com - Investing.com Canada
ALT Stock Price, Quote & Chart | ALTIMMUNE INC (NASDAQ:ALT) - ChartMill
Altimmune (MEX:ALT1) Other Liabilities for Banks - GuruFocus
Altimmune Inc (ALT) Stock Price, Quote, News & History - Benzinga
symbol__ Stock Quote Price and Forecast - CNN
Altimmune reports 48-week pemvidutide trial results at EASL By Investing.com - Investing.com Australia
Altimmune reports 48-week pemvidutide trial results at EASL - Investing.com UK
Liver disease trial: pemvidutide lowers fats, weight and blood pressure - Stock Titan
Altimmune's Q1 loss narrower than expected, revenues nil - MSN
Altimmune's Phase 2b Trial Data for Pemvidutide Demonstrates Improvements in Liver Disease - Moomoo
Altimmune to Participate in Upcoming Investor Conferences - The Manila Times
Altimmune, Inc. to Participate in Upcoming Investor Conferences in June 2026 - Quiver Quantitative
Altimmune reports positive pemvidutide trial data for MASH By Investing.com - Investing.com Nigeria
Altimmune reports positive pemvidutide trial data for MASH - Investing.com
Finanzdaten der Altimmune Inc-Aktie (ALT)
Umsatz
Nettogewinn
Free Cashflow
ENV
Altimmune Inc-Aktie (ALT) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| WEAVER GREGORY L | Chief Financial Officer |
Apr 01 '26 |
Buy |
3.15 |
10,000 |
31,499 |
38,078 |
| Durso Jerome Benedict | President and CEO |
Apr 01 '26 |
Buy |
3.14 |
15,000 |
47,100 |
47,500 |
| WEAVER GREGORY L | Chief Financial Officer |
Mar 06 '26 |
Buy |
3.54 |
5,000 |
17,700 |
28,078 |
| Durso Jerome Benedict | President and CEO |
Mar 06 '26 |
Buy |
3.54 |
20,000 |
70,790 |
32,500 |
| Roberts M Scot | Chief Scientific Officer |
Feb 02 '26 |
Option Exercise |
0.00 |
7,775 |
0 |
115,153 |
| Roberts M Scot | Chief Scientific Officer |
Jan 30 '26 |
Option Exercise |
0.00 |
9,275 |
0 |
104,670 |
| Garg Vipin K | Director |
Jan 30 '26 |
Option Exercise |
0.00 |
26,775 |
0 |
429,225 |
| Jordt Raymond M | Chief Business Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
69,765 |
| Garg Vipin K | Director |
Jan 27 '26 |
Option Exercise |
0.00 |
41,200 |
0 |
420,348 |
| Roberts M Scot | Chief Scientific Officer |
Jan 27 '26 |
Option Exercise |
0.00 |
15,850 |
0 |
100,143 |
2.60%
0.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):